​
​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie stock forecast is as follows: an average price target of $173.30 (represents a 0.91% upside from ABBV’s last price of $171.73) and a rating consensus of 'Buy', based on 31 wall street analysts offering a 1-year stock forecast.

ABBV Price Target

The average price target for AbbVie (ABBV) is $173.30 based on 1-year price targets from 31 Wall Street analysts in the past 3 months, with a price target range of $226.00 to $127.00. This represents a potential 0.91% upside from ABBV's last price of $171.73.

ABBV Analyst Ratings

Buy

According to 31 Wall Street analysts, AbbVie's rating consensus is 'Buy'. The analyst rating breakdown for ABBV stock is 0 'Strong Buy' (0.00%), 21 'Buy' (67.74%), 10 'Hold' (32.26%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AbbVie Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Evan David SeigermanBMO Capital--3.17%21.12%
Oct 31, 2024Evan David SeigermanBMO Capital--13.15%32.77%
Oct 31, 2024Charlie YangBank of America Securities--4.22%22.28%
Oct 31, 2024Geoff MeachamCitigroup--12.16%31.60%
Oct 18, 2024Geoff MeachamBank of America Securities--3.41%13.55%
Oct 17, 2024Courtney BreenBernstein--6.58%18.21%
Aug 23, 2024Christopher RaymondRaymond James--5.90%21.70%
Jul 19, 2024Evan SeigermanBMO Capital--24.41%24.61%
Jun 18, 2024Christopher RaymondRaymond James--10.88%10.64%
Jun 05, 2024Rajesh KumarHSBC--14.10%7.73%
Row per page
Go to

The latest AbbVie stock forecast, released on Nov 12, 2024 by Evan David Seigerman from BMO Capital, set a price target of $208.00, which represents a 3.17% increase from the stock price at the time of the forecast ($201.61), and a 21.12% increase from ABBV last price ($171.73).

AbbVie Price Target by Period

1M3M12M
# Anlaysts4715
Avg Price Target$218.00$211.29$200.53
Last Closing Price$171.73$171.73$171.73
Upside/Downside26.94%23.04%16.77%

In the current month, the average price target of AbbVie stock is $218.00, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 26.94% increase as opposed to AbbVie's last price of $171.73. This month's average price target is up 3.18% compared to last quarter, and up 8.71% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024Morgan StanleyOverweightOverweightHold
Oct 31, 2024CitigroupBuyBuyHold
Oct 18, 2024Bank of America SecuritiesNeutralNeutralHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 17, 2024BernsteinOutperformMarket PerformInitialise
Oct 09, 2024UBSNeutralNeutralHold
Oct 07, 2024Wells FargoBuyBuyHold
Oct 07, 2024Wells FargoOverweightOverweightHold
Oct 07, 2024Morgan StanleyOverweightOverweightHold
Oct 07, 2024BarclaysOverweightOverweightHold
Row per page
Go to

AbbVie's last stock rating was published by Morgan Stanley on Oct 31, 2024. The company gave ABBV a "Overweight" rating, the same as its previous rate.

AbbVie Financial Forecast

AbbVie Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------------$13.93B$13.87B$12.22B$15.12B$14.81B$14.58B$13.54B$14.89B$14.34B$13.96B$13.01B$13.86B$12.90B
Avg Forecast$18.20B$18.27B$17.67B$14.44B$16.93B$16.97B$16.47B$13.58B$15.69B$15.28B$14.89B$13.19B$14.79B$14.28B$14.02B$11.93B$14.03B$13.72B$13.54B$12.17B$15.33B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
High Forecast$18.71B$18.78B$18.17B$14.84B$17.41B$17.45B$16.93B$13.96B$16.14B$15.71B$15.31B$13.56B$15.23B$14.29B$14.02B$11.93B$14.34B$13.83B$13.92B$12.51B$15.76B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
Low Forecast$17.90B$17.96B$17.38B$14.20B$16.65B$16.69B$16.19B$13.35B$15.44B$15.03B$14.65B$13.00B$14.65B$14.28B$14.02B$11.93B$13.94B$13.65B$13.32B$11.97B$15.08B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
# Analysts2222222211141377491599131313137777915
Surprise %-----------------1.02%1.02%1.00%0.99%0.99%0.99%0.99%1.00%1.00%1.02%1.02%1.01%1.01%

AbbVie's average Quarter revenue forecast for Dec 23 based on 9 analysts is $14.03B, with a low forecast of $13.94B, and a high forecast of $14.34B. ABBV's average Quarter revenue forecast represents a 0.70% increase compared to the company's last Quarter revenue of $13.93B (Sep 23).

AbbVie EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts2222222211141377491599131313137777915
EBITDA-----------------$2.44B$5.11B$3.10B$6.03B$4.97B$2.03B$5.03B$6.83B$6.41B$3.98B$6.71B$1.19B$5.42B
Avg Forecast$9.03B$9.06B$8.77B$7.16B$8.40B$8.42B$8.17B$6.73B$7.79B$7.58B$7.39B$6.54B$7.34B$7.09B$6.96B$9.05B$6.96B$6.81B$6.72B$8.23B$7.47B$5.47B$5.36B$7.48B$5.47B$5.23B$4.98B$6.43B$5.01B$4.65B
High Forecast$9.28B$9.32B$9.01B$7.36B$8.64B$8.66B$8.40B$6.93B$8.01B$7.79B$7.60B$6.73B$7.56B$7.09B$6.96B$10.86B$7.12B$6.86B$6.91B$9.87B$8.96B$5.47B$5.36B$8.97B$5.47B$5.23B$4.98B$7.71B$5.01B$4.65B
Low Forecast$8.88B$8.91B$8.62B$7.04B$8.26B$8.28B$8.03B$6.62B$7.66B$7.46B$7.27B$6.45B$7.27B$7.08B$6.96B$7.24B$6.91B$6.77B$6.61B$6.58B$5.97B$5.47B$5.36B$5.98B$5.47B$5.23B$4.98B$5.14B$5.01B$4.65B
Surprise %-----------------0.36%0.76%0.38%0.81%0.91%0.38%0.67%1.25%1.23%0.80%1.04%0.24%1.17%

9 analysts predict ABBV's average Quarter EBITDA for Dec 23 to be $6.96B, with a high of $7.12B and a low of $6.91B. This is 184.91% upper than AbbVie's previous annual EBITDA (Sep 23) of $2.44B.

AbbVie Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts2222222211141377491599131313137777915
Net Income-----------------$1.78B$2.02B$239.00M$2.47B$3.95B$924.00M$4.49B$4.04B$3.18B$766.00M$3.55B$36.00M$2.31B
Avg Forecast$6.88B$6.40B$7.01B$5.04B$6.33B$5.85B$6.44B$4.65B$5.78B$5.66B$5.65B$4.61B$5.27B$5.17B$4.55B$5.40B$4.95B$5.08B$5.02B$4.91B$4.42B$6.33B$5.88B$4.46B$5.81B$5.69B$5.46B$3.40B$5.05B$4.89B
High Forecast$7.14B$6.63B$7.26B$5.23B$6.56B$6.07B$6.68B$4.82B$5.99B$5.87B$5.86B$5.12B$5.46B$5.20B$4.55B$6.48B$4.99B$5.19B$5.20B$5.89B$5.31B$6.33B$5.88B$5.35B$5.81B$5.69B$5.46B$4.08B$5.05B$4.89B
Low Forecast$6.73B$6.26B$6.86B$4.93B$6.19B$5.73B$6.31B$4.55B$5.66B$5.54B$5.53B$4.24B$5.22B$5.15B$4.55B$4.32B$4.90B$4.97B$4.91B$3.93B$3.54B$6.33B$5.88B$3.57B$5.81B$5.69B$5.46B$2.72B$5.05B$4.89B
Surprise %-----------------0.35%0.40%0.05%0.56%0.62%0.16%1.01%0.70%0.56%0.14%1.04%0.01%0.47%

AbbVie's average Quarter net income forecast for Dec 23 is $4.95B, with a range of $4.90B to $4.99B. ABBV's average Quarter net income forecast represents a 178.35% increase compared to the company's last Quarter net income of $1.78B (Sep 23).

AbbVie SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts2222222211141377491599131313137777915
SG&A-----------------$3.37B$3.27B$3.04B$3.42B$3.30B$5.41B$3.13B$3.26B$3.08B$3.16B$2.84B$3.23B$2.85B
Avg Forecast$4.28B$4.29B$4.15B$3.39B$3.98B$3.99B$3.87B$3.19B$3.69B$3.59B$3.50B$3.10B$3.48B$3.36B$3.30B$3.76B$3.30B$3.23B$3.18B$3.42B$3.56B$3.53B$3.46B$3.11B$3.53B$3.37B$3.22B$2.72B$3.23B$3.00B
High Forecast$4.40B$4.42B$4.27B$3.49B$4.09B$4.10B$3.98B$3.28B$3.79B$3.69B$3.60B$3.19B$3.58B$3.36B$3.30B$4.51B$3.37B$3.25B$3.27B$4.10B$4.28B$3.53B$3.46B$3.73B$3.53B$3.37B$3.22B$3.27B$3.23B$3.00B
Low Forecast$4.21B$4.22B$4.09B$3.34B$3.92B$3.92B$3.81B$3.14B$3.63B$3.53B$3.44B$3.06B$3.45B$3.36B$3.30B$3.01B$3.28B$3.21B$3.13B$2.73B$2.85B$3.53B$3.46B$2.49B$3.53B$3.37B$3.22B$2.18B$3.23B$3.00B
Surprise %-----------------1.05%1.03%0.89%0.96%0.94%1.56%1.01%0.92%0.91%0.98%1.04%1.00%0.95%

AbbVie's average Quarter SG&A projection for Dec 23 is $3.30B, based on 9 Wall Street analysts, with a range of $3.28B to $3.37B. The forecast indicates a -2.21% fall compared to ABBV last annual SG&A of $3.37B (Sep 23).

AbbVie EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts2222222211141377491599131313137777915
EPS-----------------$1.01$1.14$0.14$1.40$2.22$0.52$2.52$2.29$1.80$0.43$2.01$0.02$1.31
Avg Forecast$3.88$3.61$3.95$2.85$3.57$3.30$3.64$2.62$3.26$3.19$3.19$2.60$2.97$2.92$2.57$2.25$2.79$2.87$2.83$2.51$3.56$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
High Forecast$4.03$3.74$4.10$2.95$3.70$3.42$3.77$2.72$3.38$3.31$3.31$2.89$3.08$2.93$2.57$2.26$2.81$2.93$2.94$2.60$3.69$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
Low Forecast$3.80$3.53$3.87$2.78$3.50$3.23$3.56$2.57$3.19$3.12$3.12$2.39$2.94$2.91$2.57$2.25$2.76$2.80$2.77$2.45$3.48$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
Surprise %-----------------0.35%0.40%0.06%0.39%0.62%0.16%0.80%0.70%0.56%0.14%0.72%0.01%0.47%

According to 9 Wall Street analysts, AbbVie's projected average Quarter EPS for Dec 23 is $2.79, with a low estimate of $2.76 and a high estimate of $2.81. This represents a 176.53% increase compared to ABBV previous annual EPS of $1.01 (Sep 23).

AbbVie Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer--78.11%Hold
MRKMerck--29.07%Buy
JNJJohnson & Johnson--15.20%Buy
BMYBristol-Myers Squibb Company--12.48%Hold
AMGNAmgen--4.11%Buy
LLYEli Lilly and Company--3.76%Buy
ABBVAbbVie--0.91%Buy
GILDGilead Sciences---8.90%Buy

ABBV Forecast FAQ

Is AbbVie a good buy?

Yes, according to 31 Wall Street analysts, AbbVie (ABBV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 67.74% of ABBV's total ratings.

What is ABBV's price target?

AbbVie (ABBV) average price target is $173.3 with a range of $127 to $226, implying a 0.91% from its last price of $171.73. The data is based on 31 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AbbVie stock go up soon?

According to Wall Street analysts' prediction for ABBV stock, the company can go up by 0.91% (from the last price of $171.73 to the average price target of $173.3), up by 31.60% based on the highest stock price target, and down by -26.05% based on the lowest stock price target.

Can AbbVie stock reach $300?

ABBV's average twelve months analyst stock price target of $173.3 does not support the claim that AbbVie can reach $300 in the near future.

What is AbbVie's current price target trend?

4 Wall Street analysts forecast a $218 price target for AbbVie (ABBV) this month, up 26.94% from its last price of $171.73. Compared to the last 3 and 12 months, the average price target increased by 23.04% and increased by 16.77%, respectively.

What are AbbVie's analysts' financial forecasts?

AbbVie's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $63.95B (high $65.75B, low $62.89B), average EBITDA is $31.72B (high $32.62B, low $31.2B), average net income is $23.27B (high $24.13B, low $22.77B), average SG&A $15.03B (high $15.46B, low $14.79B), and average EPS is $13.13 (high $13.62, low $12.85). ABBV's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $68.57B (high $70.51B, low $67.44B), average EBITDA is $34.02B (high $34.98B, low $33.45B), average net income is $25.32B (high $26.25B, low $24.78B), average SG&A $16.12B (high $16.58B, low $15.85B), and average EPS is $14.29 (high $14.82, low $13.98).

Did the ABBV's actual financial results beat the analysts' financial forecasts?

Based on AbbVie's last annual report (Dec 2022), the company's revenue was $58.05B, which missed the average analysts forecast of $58.57B by -0.88%. Apple's EBITDA was $19.66B, missing the average prediction of $25.78B by -23.73%. The company's net income was $11.84B, missing the average estimation of $21.09B by -43.88%. Apple's SG&A was $15.26B, beating the average forecast of $13.66B by 11.69%. Lastly, the company's EPS was $6.65, missing the average prediction of $13.6 by -51.09%. In terms of the last quarterly report (Sep 2023), AbbVie's revenue was $13.93B, beating the average analysts' forecast of $13.72B by 1.52%. The company's EBITDA was $2.44B, missing the average prediction of $6.81B by -64.12%. AbbVie's net income was $1.78B, missing the average estimation of $5.08B by -65.01%. The company's SG&A was $3.37B, beating the average forecast of $3.23B by 4.55%. Lastly, the company's EPS was $1.01, missing the average prediction of $2.87 by -64.78%